TCW Group’s AtriCure ATRC Stock Holding History

TCW Group’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-17,594	Closed	-$394K	–	676
2015 Q4	$394K	Sell	17,594 -101,574	-85%	-$2.09M	﹤0.01%	650
2015 Q3	$2.61M	Sell	119,168 -149,732	-56%	-$3.74M	0.02%	296
2015 Q2	$6.63M	Sell	268,900 -12,184	-4%	-$272K	0.04%	204
2015 Q1	$5.76M	Buy	+281,084	New	+$5.45M	0.03%	363

Other funds holding ATRC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCW Group's ATRC Position: Q1 2016 in Review

TCW Group sold out of AtriCure (ATRC) in Q1 2016, closing a stake of 17,594 shares — an estimated $394K sold.

TCW Group first reported a position in ATRC in Q1 2015 and held it in 4 quarters. The position peaked at $6.63M in Q2 2015. 113 funds tracked by Wall St. Rank hold ATRC as of Q1 2016.

TCW Group reported no remaining AtriCure position as of Q1 2016 after selling out during the quarter.
TCW Group sold 17,594 AtriCure shares in Q1 2016, an estimated $394K.
TCW Group first reported a position in AtriCure in Q1 2015 and held it in 4 quarters.
TCW Group's AtriCure position peaked at $6.63M in Q2 2015.
113 funds tracked by Wall St. Rank held AtriCure as of Q1 2016.

Based on TCW Group's 13F filing for Q1 2016, filed 16 May 2016.